SCHEMBL4089155

SCHEMBL4089155

CC(=O)Nc1cccc(C2CCN(CCN)CC2)c1

nearest known ligand 0.68

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.64
MCHR1 Q99705 15/20 0.60
KCNH2 Q12809 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083055 0.93 DRD2 (0.68) DRD2MCHR1KCNH2
SCHEMBL3336956 0.89 DRD2 (0.66) DRD2MCHR1KCNH2
SCHEMBL5512301 0.87 DRD2 (0.66) DRD2
SCHEMBL3338888 0.87 DRD2 (0.69) DRD2MCHR1KCNH2
SCHEMBL4093532 0.85 DRD2 (0.61) DRD2MCHR1
SCHEMBL4399848 0.84 DRD2 (0.59) DRD2MCHR1
SCHEMBL6222128 0.83 DRD2 (0.66) DRD2MCHR1
SCHEMBL3332765 0.83 DRD2 (0.64) DRD2MCHR1KCNH2
SCHEMBL4089540 0.82 MCHR1 (0.59) DRD2MCHR1
SCHEMBL3337822 0.82 DRD2 (0.58) DRD2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2009-03-05 US disclosed
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2009-03-05 US disclosed
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2009-03-05 US disclosed
EP-1778670-A2 MEDICINAL USE OF RECEPTOR LIGANDS 7TM Pharma A/S (DK) 2007-05-02 EP disclosed
WO-2006010446-A2 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS MCHR1, MCHR2, MC1R DRD2 606/4885MCHR1 1/4885KCNH2 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.